Empowering Patient Choice: The Essential Need for a Voluntary Advance Directive Framework in Healthcare

by Clinical Neuropsychologist | Thursday, January 9, 2025 | Dementia

Abstract Background A Medicare Voluntary Advance Directive Framework (Framework) would enable the creation, storage, and sharing of advance directive documents, ensuring end-of-life care appropriately honors the individual and their care wishes, while supporting...

Pathological angiogenesis was associated with cerebrovascular lesion and neurodegeneration in Alzheimer’s disease

by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia

Abstract INTRODUCTION We investigated the specific factors driving abnormal angiogenesis in Alzheimer’s disease (AD) and its role in cerebrovascular lesions and neurodegeneration. METHODS We assessed cerebrovascular pathologies, amyloid-beta (Aβ), and tau...

Response to “Variability of cognitive changes after donanemab treatment”

by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia

Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Timothy Daly, Kasper P. Kepp, Bruno P. Imbimbo | January 8,...

Developing machine‐learning‐based amyloidogenicity predictors with Cross‐Beta DB

by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia

Abstract INTRODUCTION The importance of protein amyloidogenesis, associated with various diseases and functional roles, has driven the creation of computational predictors of amyloidogenicity. The accuracy of these predictors, particularly those utilizing artificial...

Identification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer’s disease

by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia

Abstract INTRODUCTION Sarcopenia, with its complex diagnostic process, is a likely independent predictor of poor prognosis in patients with Alzheimer’s disease (AD). However, research on the clinical characteristics and biomarkers of AD patients with sarcopenia...

Mapping amyloid beta predictors of entorhinal tau in preclinical Alzheimer’s disease

by Clinical Neuropsychologist | Wednesday, January 8, 2025 | Dementia

Abstract INTRODUCTION Amyloid beta (Aβ) plaques and hyperphosphorylated tau in the entorhinal regions are key Alzheimer’s disease (AD) markers, but the spatial Aβ pathways influencing tau pathology remain unclear. METHODS We applied predictive modeling to...